These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26320194)

  • 1. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
    Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
    Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.
    Miura I; Zhang JP; Hagi K; Lencz T; Kane JM; Yabe H; Malhotra AK; Correll CU
    Psychoneuroendocrinology; 2016 Oct; 72():1-10. PubMed ID: 27333159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.
    Lencz T; Robinson DG; Napolitano B; Sevy S; Kane JM; Goldman D; Malhotra AK
    Pharmacogenet Genomics; 2010 Sep; 20(9):569-72. PubMed ID: 20664489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.
    Huang E; Maciukiewicz M; Zai CC; Tiwari AK; Li J; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Kennedy JL
    Pharmacogenomics; 2016; 17(2):103-9. PubMed ID: 26666695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients.
    Shen YC; Chen SF; Chen CH; Lin CC; Chen SJ; Chen YJ; Luu SU
    J Psychiatr Res; 2009 Mar; 43(6):600-6. PubMed ID: 18926547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
    Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
    Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders.
    Trampush JW; Lencz T; DeRosse P; John M; Gallego JA; Petrides G; Hassoun Y; Zhang JP; Addington J; Kellner CH; Tohen M; Burdick KE; Goldberg TE; Kane JM; Robinson DG; Malhotra AK
    Schizophr Bull; 2015 Nov; 41(6):1237-47. PubMed ID: 26409223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole.
    Kwon JS; Kim E; Kang DH; Choi JS; Yu KS; Jang IJ; Shin SG;
    Eur Neuropsychopharmacol; 2008 Dec; 18(12):897-907. PubMed ID: 18786813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
    Rhindress K; Robinson DG; Gallego JA; Wellington R; Malhotra AK; Szeszko PR
    Psychol Med; 2017 Jul; 47(10):1706-1718. PubMed ID: 28193301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia.
    Alladi CG; RajKumar RP; Adithan S; Marie-Claire C; Bellivier F; Shewade DG
    Fundam Clin Pharmacol; 2019 Jun; 33(3):355-364. PubMed ID: 30332506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Episode Psychosis Research: Time to Move Forward (by Looking Backwards).
    Arango C
    Schizophr Bull; 2015 Nov; 41(6):1205-6. PubMed ID: 26392627
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.
    Correll CU; Kohegyi E; Zhao C; Baker RA; McQuade R; Salzman PM; Sanchez R; Nyilas M; Carson W
    J Am Acad Child Adolesc Psychiatry; 2017 Sep; 56(9):784-792. PubMed ID: 28838583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects.
    Koller D; Belmonte C; Lubomirov R; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Carcas A; Wojnicz A; Abad-Santos F
    J Psychopharmacol; 2018 Nov; 32(11):1212-1222. PubMed ID: 30251598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DRD2 Schizophrenia-Risk Allele Is Associated With Impaired Striatal Functioning in Unaffected Siblings of Schizophrenia Patients.
    Vink M; de Leeuw M; Luykx JJ; van Eijk KR; van den Munkhof HE; van Buuren M; Kahn RS
    Schizophr Bull; 2016 May; 42(3):843-50. PubMed ID: 26598739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
    Young RM; Lawford BR; Barnes M; Burton SC; Ritchie T; Ward WK; Noble EP
    Br J Psychiatry; 2004 Aug; 185():147-51. PubMed ID: 15286066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
    Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
    Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.